REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
23/06/2025
Voltar para busca
Dado oficial do USPTO
METIMEDI
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
24/06/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
15/11/2019
Data de registro
23/06/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/06/2020
Última transação
24/06/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Código do desenho
4
Tipo de titular
03
Localização do titular
Incheon, KR
Examinador
GILBERT, REBECCA
Unidade examinadora
L30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
MetiMedi Pharmaceuticals Co., Ltd.
Representantes
N. Christopher Norton ArentFox Schiff LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-cancer preparations; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations for immunity adjustment; Vaccines; Pharmaceutical agents for regenerating cells; Anti-inflammatory preparations; Pharmaceutical agents affecting digestive organs; Cardiovascular pharmaceutical preparations; Chemical preparations for pharmaceutical purposesfor the diagnosismonitoringtreatment and prevention of immune system related diseasescancerinfectious diseasesinflammatory disorders and oncological disorders; Chemico-pharmaceutical preparationsfor the diagnosismonitoringtreatment and prevention of immune system related diseasescancerinfectious diseasesinflammatory disorders and oncological disorders; Pharmaceuticals for medical purposes for the diagnosismonitoringtreatment and prevention of immune system related diseasescancerinfectious diseasesinflammatory disorders and oncological disorders; Antibacterial substances for medical purposes; Antibodies for medical purposes for the treatment of immune system related diseasescancerinfectious diseasesinflammatory disorders and oncological disorders; Chemical preparations for medical purposefor the diagnosismonitoringtreatment and prevention of immune system related diseasescancerinfectious diseasesinflammatory disorders and oncological disorders; Diagnostic kits for medical diagnostic purposes comprising reagents for use in disease testinghealth monitoring and more generallypredictive and preventive medicine in the fields of detecting immune system related diseasescancerinfectious diseasesinflammatory disorders and oncological disorders; Diagnostic pharmaceutical preparations for medical purposes; Antibiotics; Tumor suppressing agents; Chemotherapeutics
Classe 42
Research and development of vaccines and medicines; Crude medicines research; Medical and scientific research on adult diseases; Medical and scientific research on cancer; Pharmaceutical products development; Research on the subject of pharmaceuticals; Pharmaceutical product evaluation; Consultancy pertaining to pharmacology; Research for medical products; Medical research; Chemistry serviceschemistry consultationresearch in the field of chemistrylaboratory research and analysis in the field of chemistry; Chemical research and analysis; Research and development of medical products for others
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/03/2022
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
17/03/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
17/03/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/03/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/03/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
23/06/2020
ISPO
WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST
15/04/2020
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
13/04/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/04/2020
PUBO
PUBLISHED FOR OPPOSITION
07/04/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/03/2020
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
04/03/2020
CHPB
POST PUBLICATION AMENDMENT - ENTERED
04/03/2020
ALIE
ASSIGNED TO LIE
02/03/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
25/02/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
25/02/2020
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
25/02/2020
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
25/02/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
25/02/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
25/02/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
25/02/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
24/02/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
24/02/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
24/02/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
24/02/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
24/02/2020
DOCK
ASSIGNED TO EXAMINER
20/02/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/11/2019
NWAP
NEW APPLICATION ENTERED
19/11/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace METIMEDI ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.